One-way and two-way sensitivity analyses of point-of-care CD4 test characteristics on misclassification of patients, clinical outcomes, costs, and cost-effectiveness compared to laboratory-based CD4 tests.

Base case in bold.aDerived using test performance of percent SD = 32.6% [36], mean CD4 count (SD) of cohort = 300/µl (230/µl), and ART-eligibility threshold at CD4 count ≤250/µl,bFalse positives: patients who are ART ineligible (true CD4 count>250/µl) but are misclassified as ART eligible.cFalse negatives: patients who are ART eligible (true CD4 count ≤250/µl) but are misclassified as ART ineligible.dDiscounted at 3%/y.One-way and two-way sensitivity analyses of point-of-care CD4 test characteristics on misclassification of patients, clinical outcomes, costs, and cost-effectiveness compared to laboratory-based CD4 tests.